LifeMD, Inc. (LFMD) stock forecast and price target
Price $2.19 · data as of November 13, 2026
12-month price target
Gold marker: average target · white marker: today’s price ($2.19)
Analyst ratings
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-0.34 | −332.1% | $189M |
| Next fiscal year ends December 31, 2027 | $0.15 | +145.6% | $236M |
| Next quarter ends December 31, 2026 | $-0.07 | −232.0% | $51M |
| Quarter after ends March 31, 2027 | $0.07 | +146.2% | $55M |
Consensus of the analysts covering LifeMD, updated daily. In the last 30 days 0 estimates were raised and 1 lowered.
Our model vs. Wall Street
Analysts see 213.2% upside over 12 months. Our discounted cash flow model with moderate assumptions puts LifeMD’s intrinsic value about 84% below today’s market value, and it scores 1.8 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.
Frequently asked questions
What is the LifeMD stock price target?
The average 12-month target from 8 analysts is $6.88, 213.2% above the current price of $2.19 Targets range from $3.00 to $9.00.
Is LifeMD a buy according to analysts?
The consensus rating is “Strong buy” (7 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is LifeMD expected to earn?
Analysts expect EPS of $-0.34 for the fiscal year ending December 31, 2026 and $0.15 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.